Kodiak Sciences To Discontinue Further Development Of Tarcocimab
Kodiak Sciences Inc. (KOD) reported topline results from three Phase 3 studies of tarcocimab tedromer, a antibody biopolymer conjugate. The DAYLIGHT study evaluating the efficacy and safety of a high intensity dosing regimen of tarcocimab tedromer in 557 treatment-naïve subjects with wet Age-Related Macular Degeneration met the primary endpoint of non-inferior visual acuity gains for tarcocimab dosed monthly compared to aflibercept dosed every 8 weeks following 3 monthly loading doses.